164例颅外寡转移放疗疗效及预后分析

doi:10.3760/cma.j.issn.1004-4221.2018.07.010

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To investigate theefficacy of radiotherapy,as well as the prognostic factors of survival in patients with extracranial oligometastases. Methods A total of 164 patients who underwent intensity-modulated radiotherapy (IMRT) of the extracranial oligometastases, from January 2013 to December 2016,were enrolled in the study. The short-term efficacy,local control rate,overall survival,progression free survival and adverse effects of treatment were observed. Results Short-term efficacy was assessed within the first 1-3 months after the end of radiotherapy. The objective response rate (CR+PR) was 78.7% and the short-term efficacy is mainly related to the T stage of primary tumor (P=0.004).Until the last follow-up,all patientswith 1-,2- and 3-year LCwere 89.8%,82.5% and 74.9% respectively. Univariate analysis showed that the influencing factors of LC include tumor size and gross tumor volume dose (all P<0.05),multivariate analysis found no significant influence factors.The 1-,2- and 3-year OSwere 83.4%,69.6% and 54.6% respectively. Univariate and multivariate analysis showed that the primary tumor sources,metastasis organs,whether synchronous or adjuvant chemotherapy and short-term efficacy were independent prognostic factors in patients of OS (P<0.05).Main toxicity-associated events were grade 1-2 acute reactions,with only 6 patients experiencing grade 3 toxicity;no grade ≥ 4 toxic reactions or treatment-related deaths occurred.Conclusions Radiation therapy for the treatment of extracranial oligometastases can achieve good curative effect,is well-tolerated and has low toxicity.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Xianwen
	Zhang Huihui
	Xu Hongbo
	Zhou Yongchun
	Wang Gengming
	Zhou Yan
	Cai Feng
	Jiang Hao

Key words： Neoplasms oligometastases Extracranial oligometastases Neoplasms/radiotherapy Prognosis

Received: 25 August 2017

Fund:

Anhui Province"12^th Five-Year Plan" Clinical Medicine Key Specialist Construction Fund (01Z33)

Corresponding Authors: Jiang Hao,Email:jianghao1223@163.com

Cite this article:

Zhang Xianwen,Zhang Huihui,Xu Hongbo et al. Analysis of radiotherapy curative effect and prognostic factors in 164 patients with extracranial oligometastases[J]. Chinese Journal of Radiation Oncology, 2018, 27(7): 669-674.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.07.010 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I7/669

[1] Weichselbaum RR,Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol,2011,8(6):378-82.DOI:10.1038/nrclinonc.2011.44.
[2] Patchell R A,Tibbs P A,Walsh J W,et al. A randomized trial of surgery in the treatment of single metastases to the brain[J].N Engl J Med,1990,322(8):494-500.DOI:10.1056/ NEJM199002223220802.
[3] Kocher M,Soffietti R,Abacioglu U,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952-26001 study[J].Curr Oncol Rep,2011,13(4):255-258.DOI:10.1007/s11912-011-0180-1.
[4] Croker J,Chua B,Bernard A,et al. Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy[J]. Clin Exp Metast,2016,33(2):125-132.DOI:10.1007/s10585-015-9762-x.
[5] Brown P D,Jaeckle K,Ballman KV,et al. Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases:a randomized clinical trial[J].JAMA,2016,316(4):401-09.DOI:10.1001/jama.2016.9839.
[6] Lester-Coll NH,Dosoretz A P,Hayman J A,et al. Health state utilities for patients with brain metastases[J].Cureus,2016,8(7):e667.DOI:10.7759/cureus.667.
[7] Salama JK,Milano MT.Radical irradiation of extracranial oligometastases[J].J Clin Oncol,2014,32(26):2902-2912.DOI:10.1200/JCO.2014.55.9567.
[8] Niibe Y,Nishimura T,Inoue T,et al. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy:a multi-institutional study of 61 subjects[J].BMC Cancer, 2016,16(1):659-670.DOI:10.1186/s12885-016-2680-8.
[9] Eisenh EA,Therasse P,Bogaerts J,et al. New response evaluation criteria in solid tumours:revised RECIST guidline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.DOI:10.1016/j.ejca.2008.10.026.
[10] Cox JD,Stetz J,Pajak TF.Toxcity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J].Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346.DOI:10.1016/0360-3016(95)00060-c.
[11] Radiologists TRCO.Evidence-based indications for the use of PET-CT in the United Kingdom 2016[J].Clin Radiol,2016,71(7):e171-e188.DOI:10.1016/j.crad.2016.05.001.
[12] Dagan R,Lo SS,Redmond KJ,et al. A multi-national report on stereotactic body radiotherapy for oligometastases:Patient selection and follow-up[J].Acta Oncol,2016,55(5):633–637.DOI:10.3109/0284186X.2015.1118659.
[13] Hong JC,Salama JK.The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors:what do we know and where are we going?[J].Cancer Treat Rev,2017,(52):22-32.DOI:10.1016/j.ctrv.2016.11.003.
[14] Amendola B,Amendola M,Blanco JM,et al. Radiosurgery for liver metastases. A single institution experience[J].Rep Pract Oncol Radiother,2017,22(2):118-125.DOI:10.1016/j.rpor.2016.10.001.
[15] Park S,Urm S,Cho H.Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors[J].Cancer Res Treat,2014,46(4):403-10.DOI:10.4143/crt.2013.168.
[16] Mccammon R,Schefter TE,Gaspar LE,et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy[J].Int J Radiat Oncol Biol Phys,2009,73(1):112-118.DOI:10.1016/j.ijrobp.2008.03.062.
[17] Chang JH,Gandhidasan S,Finnigan R,et al. Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases[J].Clin Oncol,2017,29(7):e119-e125.DOI:10.1016/j.clon.20:17.02.004.
[18] Ahmed KA,Fulp WJ,Berglund AE,et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic sbrt patient selection[J].Int J Radiat Oncol Biol Phys,2015,92(4):837-42.DOI:10.1016/j.ijrobp.2015.01.036.
[19] Jingu K,Matsuo Y,Onishi H,et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer[J].Anticancer Res,2017,37(5):2709-2713.DOI:10.21873/anticanres.11621.
[20] Rieber J,Streblow J,Uhlmann L,et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group “stereotactic radiotherapy”[J].Lung Cancer,2016,97:51-58.DOI:10.1016/j.lungcan.2016.04.012.
[21] Gunjur A,Duong C,Ball D.Surgical and ablative therapies forthe management of adrenal′oligometastases′-A systematic review[J].Cancer Treat Rev,2014,40(7):838-846.DOI:10.1016 j.ctrv.2014.04.001.
[22] Yamashita H,Jingu K,Niibe Y,et al. Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer:a Japanese multi-institutional study of 237 patients[J].Radiat Oncol,2017,12(1):38.DOI:10.1186/s13014-017-0780-5.
[23] Hasselle MD,Haraf DJ,Rusthoven KE,et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer[J].J Thorac Oncol,2012,7(2):376-381.DOI:10.1097/JTO.0b013e31824166a5.
[24] 唐秋,胡巧英,朴永锋,等.不同方式治疗87例鼻咽癌放疗后肺寡转移患者的疗效分析[J].中华肿瘤杂志,2016,38(03):218-222.DOI:10.3760/cma.j.issn.0253-3766.2016.03.11.